{"DataElement":{"publicId":"3855581","version":"1","preferredName":"Chronic Myelogenous Leukemia Current Response Status","preferredDefinition":"Text term to describe the chronic myelogenous leukemia response to protocol intervention as evaluated during the current period.","longName":"CML_CURRENT_RESP_ST","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3853676","version":"1","preferredName":"Chronic Myelogenous Leukemia Current Response","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and imatinib therapy delay disease progression and prolong overall survival._The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression._Occurring in or belonging to the present time._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"3853674v1.0:3853621v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"3853674","version":"1","preferredName":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive Response","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and imatinib therapy delay disease progression and prolong overall survival.:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C3174:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3D513DE-C435-C1CC-E040-BB89AD435E94","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"ONEDATA","dateModified":"2013-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3853621","version":"1","preferredName":"Current Evaluation","preferredDefinition":"Occurring in or belonging to the present time.:Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"C25471:C25214","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Current","conceptCode":"C25471","definition":"Occurring in or belonging to the present time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3CBFDC0-2B34-5845-E040-BB89AD435489","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-12","modifiedBy":"ONEDATA","dateModified":"2013-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E3D513DE-C443-C1CC-E040-BB89AD435E94","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"KNABLEJ","dateModified":"2017-08-24","changeDescription":"8/24/17 jk transferred context and added registration status, CSI per Round 5 finalization task.  8/13/13 mc Created for CRF Harmonization per request by the Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3855495","version":"1","preferredName":"CML Current Evaluation Response Status","preferredDefinition":"Occurring in or belonging to the present time._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria._The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression._A condition or state at a particular time.","longName":"CML_CUR_EVAL_RESP_ST","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not Evaluable","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3153578","version":"1","preferredName":"Unevaluable","longName":"3153578","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93AC689E-5DB2-5D7A-E040-BB89AD430948","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-28","modifiedBy":"KUMMEROA","dateModified":"2023-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4E485A8-0492-C9B7-E040-BB89AD4349BE","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-26","modifiedBy":"ONEDATA","dateModified":"2013-08-26","deletedIndicator":"No"},{"value":"Cytogenetic Progression","valueDescription":"Cytogenetic Analysis Disease Progression","ValueMeaning":{"publicId":"3854978","version":"1","preferredName":"Cytogenetic Analysis Disease Progression","longName":"3854978","preferredDefinition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: Cancer that continues to grow or spread.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-87E2-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3F09696-2C4C-3767-E040-BB89AD431888","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"ONEDATA","dateModified":"2013-08-14","deletedIndicator":"No"},{"value":"Cytogenetic Relapse","valueDescription":"Cytogenetic Analysis Recurrent Disease","ValueMeaning":{"publicId":"3854979","version":"1","preferredName":"Cytogenetic Analysis Recurrent Disease","longName":"3854979","preferredDefinition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: The return of a disease after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-8808-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3F09696-2C56-3767-E040-BB89AD431888","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"ONEDATA","dateModified":"2013-08-14","deletedIndicator":"No"},{"value":"Karyotypic Evolution","valueDescription":"Karyotype Evolution","ValueMeaning":{"publicId":"3855498","version":"1","preferredName":"Karyotype Evolution","longName":"3855498","preferredDefinition":"Karyotype; the appearance of the chromosomal makeup of a somatic cell in an individual or species, including the number and arrangement and size and structure of the chromosomes.: The process of cumulative change over successive generations through which organisms acquire their distinguishing morphological and physiological characteristics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Karyotype","conceptCode":"C25215","definition":"The chromosomal morphology and number in somatic cells of an individual.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Evolution","conceptCode":"C16565","definition":"The process by which organism populations change over successive generations that is influenced by gene mutation and natural selection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3F09696-2CA9-3767-E040-BB89AD431888","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3F09696-2CC2-3767-E040-BB89AD431888","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"ONEDATA","dateModified":"2013-08-14","deletedIndicator":"No"},{"value":"Complete Cytogenetic Remission (CCyR)","valueDescription":"Cytogenetic Analysis Complete Remission","ValueMeaning":{"publicId":"3854980","version":"1","preferredName":"Cytogenetic Analysis Complete Remission","longName":"3854980","preferredDefinition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.: The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Analysis","conceptCode":"C18280","definition":"Techniques for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-882B-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SOKKERL","dateModified":"2018-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4E6581E-A03A-EAC1-E040-BB89AD433928","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-26","modifiedBy":"ONEDATA","dateModified":"2013-08-26","deletedIndicator":"No"},{"value":"Complete Hematologic Remission (CHR)","valueDescription":"Hematologic Complete Remission","ValueMeaning":{"publicId":"2939790","version":"1","preferredName":"Hematologic Complete Remission","longName":"2939790","preferredDefinition":"Pertaining to or related to the blood and blood-forming organs.: The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic","conceptCode":"C62780","definition":"Pertaining to or related to the blood and blood-forming organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"73556589-02F9-4C8B-E040-BB89AD436005","latestVersionIndicator":"Yes","beginDate":"2009-09-11","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4E6581E-A04E-EAC1-E040-BB89AD433928","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-26","modifiedBy":"ONEDATA","dateModified":"2013-08-26","deletedIndicator":"No"},{"value":"Major Molecular Remission (MMR)","valueDescription":"Major Molecular Analysis Response","ValueMeaning":{"publicId":"3855499","version":"1","preferredName":"Major Molecular Analysis Response","longName":"3855499","preferredDefinition":"Greater or bigger in amount, extent, or size.: Techniques for studying or analyzing the genetic composition and mechanisms of living organisms at the molecular level. May refer to the understanding and manipulation of genes (DNA).: An abatement in intensity or degree (as in the manifestations of a disease).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Major","conceptCode":"C45368","definition":"Greater or bigger in amount, extent, or size.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Molecular Analysis","conceptCode":"C19770","definition":"A laboratory procedure that involves the study of tissues, cells, and fluids using DNA/RNA analysis techniques for the identification of characteristics and abnormalities at the molecular level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Remission","conceptCode":"C18246","definition":"An abatement in intensity or degree (as in the manifestations of a disease).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3F09696-2CD0-3767-E040-BB89AD431888","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4E6581E-A062-EAC1-E040-BB89AD433928","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-26","modifiedBy":"ONEDATA","dateModified":"2013-08-26","deletedIndicator":"No"},{"value":"Emergence of an Acquired ABL Kinase Domain Mutation","valueDescription":"Acquired BCR-ABL TKI-Resistant Mutation","ValueMeaning":{"publicId":"4639971","version":"1","preferredName":"Acquired BCR-ABL TKI-Resistant Mutation","longName":"4639971","preferredDefinition":"Of or relating to a medical condition or characteristic that is not present at birth but develops subsequently.: A molecular genetic abnormality in the kinase domain of the BCR-ABL fusion gene that results in resistance to tyrosine kinase inhibitors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acquired","conceptCode":"C85869","definition":"Of or relating to a medical condition or characteristic that is not present at birth but develops subsequently.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"BCR-ABL TKI-Resistant Mutation","conceptCode":"C110963","definition":"A molecular genetic abnormality in the kinase domain of the BCR-ABL fusion gene that results in resistance to tyrosine kinase inhibitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A7486FF-B5CB-CEE5-E050-BB89AD43434C","latestVersionIndicator":"Yes","beginDate":"2014-12-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0A7486FF-B5E4-CEE5-E050-BB89AD43434C","beginDate":"2013-08-14","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-12-17","modifiedBy":"ONEDATA","dateModified":"2014-12-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3865328","version":"1","preferredName":"Current Evaluation Response Status","preferredDefinition":"Occurring in or belonging to the present time.:Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.:A condition or state at a particular time.","longName":"C25471:C25214:C50995:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Current","conceptCode":"C25471","definition":"Occurring in or belonging to the present time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4E2F160-F295-E72E-E040-BB89AD430752","latestVersionIndicator":"Yes","beginDate":"2013-08-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-26","modifiedBy":"ONEDATA","dateModified":"2013-08-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E3F09696-2C37-3767-E040-BB89AD431888","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"KNABLEJ","dateModified":"2017-08-24","changeDescription":"8/24/17 jk transferred context and added registration status, CSI per Round 5 finalization task.  8/14/13 mc Created for CRF Harmonization per request by Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2192345","version":"1","longName":"Data Standards","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2859963","version":"1","longName":"Standard CRFs","context":"NCIP"},{"publicId":"3813676","version":"1","longName":"Response CRF","context":"NCIP"}]},{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"3813675","version":"1","longName":"Response","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Current response (CML)","type":"Preferred Question Text","description":"Current response (CML)","url":null,"context":"NCI Standards"},{"name":"Prior Question Text","type":"Standard Alternate Question Text","description":"Current Response (CML)","url":null,"context":"NCI Standards"}],"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"E3F3FD8B-3707-C859-E040-BB89AD43580F","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"KNABLEJ","dateModified":"2017-08-24","changeDescription":"8/24/17 jk transferred context, updated case in question, and added registration status per Round 5 finalization task.  8/14/13 mc Created per request by CRF Harmonization Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}